Emergent BioSolutions

$80.41
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.24 (+1.57%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell EBS and other stocks, options, and ETFs commission-free!

About EBS

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD. The listed name for EBS is Emergent Biosolutions, Inc.

CEO

Robert G. Kramer

Employees

1,834

Headquarters

Gaithersburg, Maryland

Founded

1998

Market Cap

4.26B

Price-Earnings Ratio

25.61

Dividend Yield

—

Average Volume

665.32K

High Today

$81.75

Low Today

$78.88

Open Price

$79.66

Volume

515.71K

52 Week High

$137.61

52 Week Low

$46.37

Collections

Analyst Ratings

75%

of 8 ratings

Buy

75%

Hold

25%

Sell

EBS Earnings

-$0.13

$0.64

$1.42

$2.19

Q1 FY19

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 18, After Hours